Credence MedSystems wins ISO 13485 certification

Credence MedSystems said it has earned ISO 13485:2016 certification for its quality management system, a milestone the company says strengthens its bid to become a ready-to-supply partner for pharma and biopharma companies. The certification from BSI could help support supplier qualification and manufacturing readiness for injectable drug delivery programs.

Why it matters: - ISO 13485 certification is a key signal for pharmaceutical and biotechnology companies evaluating suppliers for combination products and injectable drug delivery systems. - The certification can support supplier qualification, manufacturing readiness and confidence in a partner’s quality systems before commercialization. - Credence MedSystems is positioning the milestone as a step from technology developer to ready-to-supply partner.

What happened: - Credence MedSystems said on Sept. 29, 2026, that it achieved ISO 13485:2016 certification for its Quality Management System. - The certificate was issued by BSI. - The company develops drug delivery technologies for pharmaceutical and biotechnology customers.

The details: - ISO 13485 is an internationally recognized standard for the design and manufacture of medical-device-related products. - The certification covers Credence’s quality management system. - Credence says its business model centers on solving injectable drug delivery challenges while supporting quality, manufacturing and supply needs. - The company’s “Innovation Without Change®” approach is built around proven primary components and established manufacturing processes. - Credence says that approach is meant to reduce implementation risk and operational disruption for pharmaceutical partners. - The company’s portfolio includes the Companion® Platform, the Dual Chamber Syringe Platform and the Metered Dosing Platform. - The Companion® Platform is a prefilled syringe system with passive integrated needle safety across 1 mL, 2.25 mL, 3 mL and 5 mL formats. - Credence says the expanded Companion® platform supports larger-volume injectable therapies. - The Dual Chamber Syringe Platform supports reconstitution or sequential injection while keeping components separate before administration. - Credence says the dual-chamber offering is supported by filling, assembly, labeling and packaging capabilities through specialized partners. - The Metered Dosing Platform supports precision microliter dosing for single- or multi-dose ophthalmic, aesthetic and other precision therapies. - Credence also develops technologies aimed at needle clogging and high-viscosity formulations.

Between the lines: - The certification suggests Credence is trying to make its pitch to drugmakers stronger on manufacturing credibility, not just product innovation. - For pharma buyers, the shift matters because drug delivery vendors often need to prove they can support a program through scale-up and commercial supply, not only early development. - Credence is using the certification to reinforce a broader message: its platforms are designed to be adaptable without forcing major changes in manufacturing workflows.

What's next: - Credence says ISO 13485 certification will help it support pharma and biopharma collaborators as they move programs toward commercialization. - The company is likely to use the milestone to deepen discussions with partners seeking injectable delivery solutions backed by quality and manufacturing systems. - Credence’s contact page lists more information and info@CredenceMed.com. - The company also lists its LinkedIn page at Credence MedSystems on LinkedIn.

The bottom line: - Credence MedSystems has added a major quality credential that could make its injectable drug delivery platforms more attractive to pharma and biopharma buyers focused on commercialization readiness.